Sudeep Pharma (SUDEEPPHRM) — Announcement

📢 Key Event
Q1 FY27 results show 27% revenue growth to ₹158.3 crores

🔄 What Changed
PAT growth outpaced revenue growth at 30% YoY

🔮 What's Next
Greenfield expansion completion targeted for early CY27

💡 Investor Takeaway
Strong margin resilience and growth in high-value segments support near-term expansion plans.

Sudeep Pharma Limited reported Q1 FY27 results with revenue rising 27% YoY to ₹158.3 crores, EBITDA up 25% to ₹54.9 crores, and PAT surging 30% to ₹40.6 crores, driven by strong performance in specialty ingredients and pharma nutrition segments. The company highlighted progress on its Greenfield expansion targeting early CY27 completion and strategic moves in high-growth areas like battery materials.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUDEEPPHRM ✨ Ask AI About This

About Sudeep Pharma Limited (SUDEEPPHRM)

Chemicals · Chemicals & Petrochemicals · Listed on NSE

Market Cap: ₹7,329.8 Cr

View full SUDEEPPHRM stock details →

📡 Get AI alerts when SUDEEPPHRM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUDEEPPHRM — Free

💡 Ask AI about this filing

"How does the Greenfield expansion capacity of 51200 units impact future margins?" "What is the expected revenue contribution from the UK vitamin/mineral acquisition?" "When will SAM project revenue become material to overall financials?"

Ask AI Free →

📊 More SUDEEPPHRM filings

See all SUDEEPPHRM filings →

🔥 Also filed on 4 August 2026

UNIMECH Unimech Aerospace and Manufacturing Limited Annual Report VRLLOG VRL Logistics Limited Financial Results EMAMILTD Emami Limited Financial Results WORTHPERI Worth Peripherals Limited Financial Results PRICOLLTD Pricol Limited Financial Results JYOTISTRUC Jyoti Structures Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUDEEPPHRM files new disclosures

Track SUDEEPPHRM filings, board meetings, and corporate actions. Free email alerts at 5 PM.